OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SMSP56

SMS Pharmaceuticals Ltd

PharmaceuticalsVerified

SMS Pharmaceuticals Ltd maintains a debt-to-equity ratio of 0.49, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.71, suggesting it can cover short-term obligations but with limited buffer. However, the company has negative net cash after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing. The company's profitability metrics show a return on equity (ROE) of 10.81% and a return on assets (ROA) of 6.00%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The operating margin, calculated as operating income of INR 1,046.67 million on revenue of INR 7,827.48 million, is 13.37%, which is a strong indicator of cost control and pricing power. The company's revenue is concentrated in a few key segments and geographic regions, with the majority of its sales coming from the domestic market. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulate it from foreign exchange volatility. The company's revenue concentration in a single geographic region could pose a risk if domestic demand weakens or regulatory pressures increase. The company's growth trajectory is mixed. Revenue for the latest period was INR 7,827.48 million, and while the outlook for the current fiscal year is positive, the next fiscal year's growth is expected to be more moderate. The company's capital expenditure of INR 1,233.79 million indicates a focus on maintaining and expanding production capacity, which is a positive sign for long-term growth. However, the company's free cash flow is negative at INR -250.31 million, which may limit its ability to fund growth initiatives without external financing. The company's risk profile is characterized by medium liquidity risk and low dilution potential. The risk assessment highlights the negative net cash position as a key flag, which could necessitate additional debt or equity financing in the near term. The company has not indicated any immediate plans for share dilution, and the dilution potential is assessed as low, suggesting that the company is not currently under pressure to raise capital through equity issuance. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial statements and disclosures are consistent with its historical performance, and there are no indications of significant regulatory or legal challenges that would impact its operations.

30-day price · SMSP-49.25 (-11.8%)
Low$361.70High$447.80Close$369.15As of25 May, 00:00 UTC
Profile
CompanySMS Pharmaceuticals Ltd
TickerSMSP.NS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. SMS Pharmaceuticals Ltd is a pharmaceutical company that develops, manufactures, and markets generic and branded drugs, primarily in the Indian domestic market and for export.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

SMS Pharmaceuticals Ltd maintains a debt-to-equity ratio of 0.49, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.71, suggesting it can cover short-term obligations but with limited buffer. However, the company has negative net cash after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing. The company's profitability metrics show a return on equity (ROE) of 10.81% and a return on assets (ROA) of 6.00%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The operating margin, calculated as operating income of INR 1,046.67 million on revenue of INR 7,827.48 million, is 13.37%, which is a strong indicator of cost control and pricing power. The company's revenue is concentrated in a few key segments and geographic regions, with the majority of its sales coming from the domestic market. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulate it from foreign exchange volatility. The company's revenue concentration in a single geographic region could pose a risk if domestic demand weakens or regulatory pressures increase. The company's growth trajectory is mixed. Revenue for the latest period was INR 7,827.48 million, and while the outlook for the current fiscal year is positive, the next fiscal year's growth is expected to be more moderate. The company's capital expenditure of INR 1,233.79 million indicates a focus on maintaining and expanding production capacity, which is a positive sign for long-term growth. However, the company's free cash flow is negative at INR -250.31 million, which may limit its ability to fund growth initiatives without external financing. The company's risk profile is characterized by medium liquidity risk and low dilution potential. The risk assessment highlights the negative net cash position as a key flag, which could necessitate additional debt or equity financing in the near term. The company has not indicated any immediate plans for share dilution, and the dilution potential is assessed as low, suggesting that the company is not currently under pressure to raise capital through equity issuance. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial statements and disclosures are consistent with its historical performance, and there are no indications of significant regulatory or legal challenges that would impact its operations.
Key takeaways
  • SMS Pharmaceuticals Ltd has a conservative capital structure with a debt-to-equity ratio of 0.49.
  • The company's ROE of 10.81% and ROA of 6.00% indicate strong profitability relative to its equity and asset base.
  • Revenue is concentrated in the domestic market, which may limit diversification benefits.
  • The company's free cash flow is negative, which could constrain its ability to fund growth without external financing.
  • The company's liquidity position is assessed as medium, with a current ratio of 1.71.
  • The company has low dilution potential, suggesting no immediate need for equity financing.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$7.83B
Gross profit$2.79B
Operating income$1.05B
Net income$691.4M
R&D
SG&A
D&A
SBC
Operating cash flow$817.1M
CapEx-$1.23B
Free cash flow-$250.3M
Total assets$11.53B
Total liabilities$5.13B
Total equity$6.40B
Cash & equivalents
Long-term debt$3.11B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$6.40B
Net cash-$3.11B
Current ratio1.7
Debt/Equity0.5
ROA6.0%
ROE10.8%
Cash conversion1.2%
CapEx/Revenue-15.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricSMSPActivity
Op margin13.4%2.4% medp25 -91.8% · p75 12.5%top quartile
Net margin8.8%1.2% medp25 -98.4% · p75 10.4%above median
Gross margin35.6%45.6% medp25 29.8% · p75 66.7%below median
CapEx / revenue-15.8%-5.2% medp25 -15.8% · p75 -1.7%below median
Debt / equity49.0%9.3% medp25 0.1% · p75 43.8%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 17:30 UTC#4f68a778
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 12:02 UTCJob: e507daff